OncoMatch/Clinical Trials/NCT06385730
Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
Is NCT06385730 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including neoadjuvant anti-PD-1 and neoadjuvant anti-PD-1 with LDRT for esophageal cancer.
Treatment: neoadjuvant anti-PD-1 · neoadjuvant anti-PD-1 with LDRT — The investigators will conduct a prospective phase 2 study to evaluate the efficacy and safety of neoadjuvant PD-1 blockade monotherapy with toripalimab in elderly patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage T1N1-3M0, T2-3N0-3M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
Have not received any anti-tumor treatment for esophageal cancer in the past, including radiotherapy, chemotherapy, surgery, etc.
Cannot have received: chemotherapy
Have not received any anti-tumor treatment for esophageal cancer in the past, including radiotherapy, chemotherapy, surgery, etc.
Cannot have received: surgery
Have not received any anti-tumor treatment for esophageal cancer in the past, including radiotherapy, chemotherapy, surgery, etc.
Cannot have received: immunotherapy
anti-tumor interventions such as radiotherapy, chemotherapy, immunotherapy or other medications
Lab requirements
Blood counts
NE ≥ 1.5×10^9/L; PLT ≥ 100×10^9/L; HGB ≥ 90 g/L
Kidney function
sCr ≤ 1.5×ULN or CrCl ≥ 50 mL/min (Cocheroft-Gault)
Liver function
bilirubin ≤ 1.5×ULN; ALT ≤ 2.5×ULN; AST ≤ 2.5×ULN
Blood routine: NE≥1.5×10^9/L; PLT≥100×10^9/L; HGB≥90 g/L; bilirubin≤ 1.5×ULN; ALT≤2.5×ULN; AST≤2.5×ULN; sCr≤1.5×ULN or CrCl≥50 mL/min（Cocheroft-Gault); INR≤1.5
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify